See more : Force Motors Limited (FORCEMOT.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Meridian Bioscience, Inc. (VIVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Meridian Bioscience, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Rackspace Technology, Inc. (RXT) Income Statement Analysis – Financial Results
- Kredyt Inkaso S.A. (KRI.WA) Income Statement Analysis – Financial Results
- Changqing Machinery Company Limited (603768.SS) Income Statement Analysis – Financial Results
- American Transportation Holdings, Inc. (ATHI) Income Statement Analysis – Financial Results
- Navidea Biopharmaceuticals, Inc. (NAVB) Income Statement Analysis – Financial Results
Meridian Bioscience, Inc. (VIVO)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.meridianbioscience.com
About Meridian Bioscience, Inc.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 333.02M | 317.90M | 253.67M | 201.01M | 213.57M | 200.77M | 196.08M | 194.83M | 188.83M | 188.69M | 173.54M | 159.72M | 143.00M | 148.27M | 139.64M | 122.96M | 108.41M | 92.97M | 79.61M | 65.86M | 59.10M | 56.53M | 57.10M | 54.40M | 33.20M | 35.20M | 29.40M | 25.10M | 21.90M | 16.20M | 14.00M | 11.10M | 8.50M | 6.20M | 5.60M | 5.20M | 6.30M | 4.90M |
| Cost of Revenue | 144.66M | 116.75M | 97.42M | 82.69M | 83.11M | 75.94M | 68.30M | 72.95M | 71.59M | 67.64M | 63.66M | 60.43M | 54.53M | 55.49M | 53.16M | 48.02M | 43.74M | 38.15M | 33.93M | 27.58M | 24.51M | 25.82M | 16.84M | 13.80M | 7.70M | 9.30M | 6.80M | 6.00M | 5.80M | 4.00M | 4.00M | 3.60M | 3.10M | 2.10M | 1.80M | 1.60M | 1.40M | 800.00K |
| Gross Profit | 188.36M | 201.15M | 156.25M | 118.33M | 130.46M | 124.83M | 127.79M | 121.88M | 117.24M | 121.04M | 109.88M | 99.30M | 88.48M | 92.78M | 86.48M | 74.94M | 64.67M | 54.82M | 45.68M | 38.29M | 34.60M | 30.71M | 40.26M | 40.60M | 25.50M | 25.90M | 22.60M | 19.10M | 16.10M | 12.20M | 10.00M | 7.50M | 5.40M | 4.10M | 3.80M | 3.60M | 4.90M | 4.10M |
| Gross Profit Ratio | 56.56% | 63.27% | 61.60% | 58.86% | 61.09% | 62.18% | 65.17% | 62.56% | 62.09% | 64.15% | 63.31% | 62.17% | 61.87% | 62.58% | 61.93% | 60.95% | 59.65% | 58.97% | 57.38% | 58.13% | 58.54% | 54.32% | 70.51% | 74.63% | 76.81% | 73.58% | 76.87% | 76.10% | 73.52% | 75.31% | 71.43% | 67.57% | 63.53% | 66.13% | 67.86% | 69.23% | 77.78% | 83.67% |
| Research & Development | 24.34M | 23.91M | 23.73M | 17.95M | 16.87M | 15.68M | 13.82M | 12.61M | 12.55M | 10.79M | 10.28M | 9.82M | 8.57M | 8.43M | 6.18M | 6.09M | 4.80M | 3.82M | 4.36M | 3.88M | 2.89M | 3.36M | 2.26M | 2.00M | 2.00M | 1.50M | 1.50M | 1.40M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 57.15M | 52.34M | 46.43M | 34.59M | 34.49M | 33.04M | 30.57M | 27.62M | 27.39M | 30.52M | 27.39M | 25.43M | 18.77M | 16.34M | 35.95M | 33.83M | 32.99M | 30.78M | 26.66M | 21.62M | 20.51M | 22.47M | 23.03M | 21.00M | 12.20M | 11.50M | 10.40M | 9.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 31.27M | 26.78M | 26.49M | 28.45M | 34.47M | 32.10M | 29.87M | 25.60M | 24.91M | 22.42M | 22.92M | 24.01M | 18.76M | 19.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 88.42M | 79.12M | 72.91M | 63.03M | 68.96M | 65.14M | 60.44M | 53.22M | 52.30M | 52.94M | 50.31M | 49.44M | 37.53M | 35.58M | 35.95M | 33.83M | 32.99M | 30.78M | 26.66M | 21.62M | 20.51M | 22.47M | 23.03M | 21.00M | 12.20M | 11.50M | 10.40M | 9.10M | 8.10M | 7.50M | 6.80M | 5.80M | 4.20M | 3.50M | 3.50M | 3.10M | 2.30M | 2.20M |
| Other Expenses | -350.00K | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.21M | 11.07M | 4.81M | 5.70M | 2.90M | 3.00M | 2.20M | 2.00M | 1.70M | 1.10M | 600.00K | 400.00K | 700.00K | 500.00K | 400.00K | 300.00K | 200.00K | 200.00K |
| Operating Expenses | 112.41M | 107.63M | 96.64M | 80.98M | 85.83M | 80.82M | 74.25M | 65.82M | 64.85M | 63.73M | 60.58M | 59.27M | 46.10M | 44.00M | 42.13M | 39.91M | 37.79M | 34.60M | 31.02M | 25.50M | 24.60M | 36.90M | 30.10M | 28.70M | 17.10M | 16.00M | 14.10M | 12.50M | 11.20M | 8.60M | 7.40M | 6.20M | 4.90M | 4.00M | 3.90M | 3.40M | 2.50M | 2.40M |
| Cost & Expenses | 257.07M | 224.38M | 194.06M | 163.67M | 168.94M | 156.76M | 142.55M | 138.77M | 136.44M | 131.37M | 124.25M | 119.69M | 100.62M | 99.50M | 95.29M | 87.93M | 81.53M | 72.75M | 64.95M | 53.08M | 49.11M | 62.72M | 46.94M | 42.50M | 24.80M | 25.30M | 20.90M | 18.50M | 17.00M | 12.60M | 11.40M | 9.80M | 8.00M | 6.10M | 5.70M | 5.00M | 3.90M | 3.20M |
| Interest Income | 17.00K | 0.00 | 142.00K | 681.00K | 418.00K | 171.00K | 67.00K | 23.00K | 25.00K | 44.00K | 42.00K | 115.00K | 124.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.19M | 1.88M | 2.63M | 1.95M | 1.52M | 1.64M | 897.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 16.51M | 15.29M | 13.57M | 9.96M | 7.92M | 8.12M | 6.63M | 5.22M | 5.56M | 5.62M | 6.60M | 5.70M | 4.69M | 4.36M | 4.47M | 4.40M | 5.29M | 4.25M | 4.08M | 3.78M | 3.72M | 4.75M | 4.81M | 5.70M | 2.90M | 3.00M | 2.20M | 2.00M | 1.70M | 1.10M | 600.00K | 400.00K | 700.00K | 500.00K | 400.00K | 300.00K | 200.00K | 200.00K |
| EBITDA | 72.02M | 107.62M | 75.49M | 43.47M | 39.82M | 46.19M | 58.17M | 60.28M | 52.39M | 62.99M | 56.31M | 40.03M | 46.09M | 48.78M | 50.46M | 41.08M | 33.34M | 23.85M | 17.27M | 15.37M | 11.96M | -10.16M | 11.75M | 11.00M | 11.00M | 12.70M | 11.10M | 7.90M | 5.60M | 4.20M | 3.30M | 2.00M | 1.70M | 900.00K | 700.00K | 900.00K | 2.80M | 2.30M |
| EBITDA Ratio | 21.63% | 33.85% | 29.76% | 21.62% | 18.65% | 23.01% | 29.67% | 30.94% | 30.54% | 33.38% | 32.45% | 28.93% | 32.23% | 36.21% | 36.14% | 33.41% | 30.75% | 25.65% | 21.70% | 23.34% | 20.24% | -17.97% | 20.58% | 20.22% | 33.13% | 36.08% | 37.76% | 31.47% | 25.57% | 25.93% | 23.57% | 18.02% | 20.00% | 14.52% | 12.50% | 17.31% | 44.44% | 46.94% |
| Operating Income | 55.51M | 93.03M | 61.32M | 32.70M | 31.58M | 37.38M | 51.38M | 56.06M | 52.39M | 57.31M | 49.30M | 40.03M | 41.14M | 48.78M | 44.35M | 35.03M | 26.88M | 20.22M | 14.66M | 12.79M | 9.99M | -12.51M | 10.15M | 11.90M | 8.40M | 9.90M | 8.50M | 6.60M | 4.90M | 3.60M | 2.60M | 1.30M | 500.00K | 100.00K | -100.00K | 200.00K | 2.40M | 1.70M |
| Operating Income Ratio | 16.67% | 29.27% | 24.18% | 16.27% | 14.79% | 18.62% | 26.20% | 28.77% | 27.75% | 30.38% | 28.41% | 25.06% | 28.77% | 32.90% | 31.76% | 28.49% | 24.79% | 21.75% | 18.41% | 19.42% | 16.91% | -22.13% | 17.78% | 21.88% | 25.30% | 28.13% | 28.91% | 26.29% | 22.37% | 22.22% | 18.57% | 11.71% | 5.88% | 1.61% | -1.79% | 3.85% | 38.10% | 34.69% |
| Total Other Income/Expenses | -1.19M | -2.58M | -2.03M | -1.14M | -1.20M | -953.00K | -734.00K | -997.00K | -284.00K | 48.00K | 420.00K | 467.00K | 262.00K | -16.02M | 1.64M | 1.65M | 1.17M | -620.00K | -1.46M | -1.20M | -1.75M | -2.40M | -3.22M | -6.60M | -300.00K | -200.00K | 400.00K | -700.00K | -1.00M | -500.00K | 100.00K | 300.00K | 500.00K | 300.00K | 400.00K | 400.00K | 200.00K | 400.00K |
| Income Before Tax | 54.32M | 90.45M | 59.29M | 31.56M | 30.38M | 36.43M | 50.64M | 55.06M | 52.11M | 57.36M | 49.72M | 40.50M | 41.40M | 49.32M | 45.99M | 36.68M | 28.05M | 19.60M | 13.20M | 11.59M | 8.24M | -14.91M | 6.94M | 5.30M | 8.10M | 9.70M | 8.90M | 5.90M | 3.90M | 3.10M | 2.70M | 1.60M | 1.00M | 400.00K | 300.00K | 600.00K | 2.60M | 2.10M |
| Income Before Tax Ratio | 16.31% | 28.45% | 23.37% | 15.70% | 14.22% | 18.14% | 25.83% | 28.26% | 27.59% | 30.40% | 28.65% | 25.36% | 28.95% | 33.26% | 32.94% | 29.83% | 25.88% | 21.08% | 16.58% | 17.60% | 13.95% | -26.37% | 12.15% | 9.74% | 24.40% | 27.56% | 30.27% | 23.51% | 17.81% | 19.14% | 19.29% | 14.41% | 11.76% | 6.45% | 5.36% | 11.54% | 41.27% | 42.86% |
| Income Tax Expense | 11.86M | 19.04M | 13.11M | 7.18M | 6.53M | 14.87M | 18.42M | 19.52M | 17.37M | 19.33M | 16.35M | 13.67M | 14.75M | 16.56M | 15.79M | 9.96M | 9.73M | 7.03M | 4.01M | 4.57M | 3.21M | -4.63M | -173.00K | 2.90M | 3.10M | 3.70M | 3.60M | 2.40M | 1.50M | 1.20M | 1.00M | 600.00K | 400.00K | 100.00K | 100.00K | 100.00K | 1.20M | 1.00M |
| Net Income | 42.46M | 71.41M | 46.19M | 24.38M | 23.85M | 21.56M | 32.23M | 35.54M | 34.74M | 38.03M | 33.37M | 26.83M | 26.65M | 32.76M | 30.20M | 26.72M | 18.33M | 12.57M | 9.19M | 7.02M | 5.03M | -10.28M | 7.11M | 2.40M | 5.00M | 6.00M | 5.30M | 3.50M | 2.40M | 1.90M | 1.70M | 1.00M | 600.00K | 300.00K | 200.00K | 500.00K | 1.40M | 1.10M |
| Net Income Ratio | 12.75% | 22.46% | 18.21% | 12.13% | 11.17% | 10.74% | 16.44% | 18.24% | 18.40% | 20.16% | 19.23% | 16.80% | 18.63% | 22.09% | 21.63% | 21.73% | 16.90% | 13.52% | 11.54% | 10.66% | 8.51% | -18.18% | 12.45% | 4.41% | 15.06% | 17.05% | 18.03% | 13.94% | 10.96% | 11.73% | 12.14% | 9.01% | 7.06% | 4.84% | 3.57% | 9.62% | 22.22% | 22.45% |
| EPS | 0.96 | 1.62 | 1.07 | 0.57 | 0.56 | 0.51 | 0.77 | 0.85 | 0.84 | 0.92 | 0.81 | 0.66 | 0.66 | 0.81 | 0.75 | 0.68 | 0.47 | 0.36 | 0.27 | 0.21 | 0.15 | -0.31 | 0.22 | 0.07 | 0.15 | 0.19 | 0.16 | 0.13 | 0.09 | 0.07 | 0.06 | 0.04 | 0.03 | 0.01 | 0.01 | 0.02 | 0.06 | 0.05 |
| EPS Diluted | 0.96 | 1.62 | 1.07 | 0.57 | 0.56 | 0.51 | 0.76 | 0.85 | 0.83 | 0.91 | 0.80 | 0.65 | 0.65 | 0.80 | 0.74 | 0.66 | 0.46 | 0.35 | 0.27 | 0.21 | 0.15 | -0.31 | 0.22 | 0.07 | 0.15 | 0.19 | 0.16 | 0.12 | 0.08 | 0.07 | 0.06 | 0.04 | 0.03 | 0.01 | 0.01 | 0.02 | 0.06 | 0.05 |
| Weighted Avg Shares Out | 44.01M | 44.01M | 43.17M | 42.90M | 42.75M | 42.19M | 42.01M | 41.66M | 41.46M | 41.23M | 41.08M | 40.72M | 40.52M | 40.39M | 40.09M | 39.58M | 39.13M | 35.21M | 33.44M | 32.99M | 32.90M | 32.83M | 32.77M | 32.37M | 32.35M | 32.27M | 33.00M | 27.80M | 26.97M | 28.47M | 29.39M | 28.10M | 22.48M | 22.48M | 22.48M | 22.48M | 24.21M | 22.48M |
| Weighted Avg Shares Out (Dil) | 44.01M | 44.01M | 43.17M | 42.90M | 42.75M | 42.57M | 42.39M | 42.01M | 41.91M | 41.90M | 41.61M | 41.36M | 41.15M | 41.11M | 41.03M | 40.74M | 40.16M | 36.16M | 34.33M | 33.64M | 33.21M | 32.83M | 32.97M | 32.81M | 33.08M | 32.27M | 33.00M | 28.39M | 28.39M | 28.47M | 29.39M | 28.10M | 22.48M | 22.48M | 22.48M | 22.48M | 24.21M | 22.48M |
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024...
Catheter Precision Continues to Expand Clinical Data and Acceptance of VIVO
FORT MILL, SC / ACCESSWIRE / October 2, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a company dedicated in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced several updates for their VIVO non-invasive mapping...
Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of...
Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began...
Catheter Precision, Inc. Announces Receipt of First Purchase Order for VIVO from Distributor in Middle East
FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial...
POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL
- OCM™ was significantly better than comparators at halting proliferation of MRSA and PA –- OCM™ recorded the lowest bacterial counts of any treatment arm –- OCM™ showed significantly faster formation of new tissue in MRSA-infected wounds than any other...
Medical Devices Stock Pumps Up Buy Point With New Innovations
After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up Buy Point With New Innovations appeared first...
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire
This quartet of stocks has plenty of growth ahead and is already profitable.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical...
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR
NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Meridian Bioscience, Inc....
Source: https://incomestatements.info
Category: Stock Reports